CD8+ T Cell Exhaustion and Tumor Immune Checkpoint Blockade: Mechanisms, Heterogeneity, and Combination Intervention Strategies

Gang Liu

Advances in World Medical Research ›› 2026, Vol. 2 ›› Issue (3) : 96 -104.

PDF (273KB)
Advances in World Medical Research ›› 2026, Vol. 2 ›› Issue (3) :96 -104. DOI: 10.71204/dkzdp879
research-article
CD8+ T Cell Exhaustion and Tumor Immune Checkpoint Blockade: Mechanisms, Heterogeneity, and Combination Intervention Strategies
Author information +
History +
PDF (273KB)

Abstract

CD8+ T cells are the core effector cells in anti-tumor immunity, but under continuous tumor antigen stimulation and inhibitory microenvironment, they gradually enter a state of dysfunction, showing reduced effector secretion, decreased proliferation, persistent expression of inhibitory receptors, and abnormal metabolic adaptation, which are driven by a unified transcriptional, epigenetic, metabolic, and microenvironmental exhaustion program. T cell exhaustion is a major reason why immune checkpoint blockade (ICB) therapy has limited effectiveness and also a key target for combination treatment strategies. In recent years, single-cell sequencing, spatial transcriptomics, and functional immunology studies have shown that exhausted T cells are not a single state-they include heterogeneous subgroups such as progenitor exhausted T cells (Tpex), intermediate exhausted T cells, and terminal exhausted T cells. Blocking PD-1/PD-L1 and CTLA-4 can partly restore T cell function, but primary and secondary resistance are still common. This article reviews the unified mechanisms of CD8+ T cell exhaustion and, organized around the axis of 'mechanism-heterogeneity-ICB response-combination strategies', explores potential strategies for immune checkpoint blockade related to CD8+ T cell exhaustion, and also discusses biomarkers and future research directions.

Keywords

CD8+ T Cells / T Cell Exhaustion / Immune Checkpoint Blockade / Tumor Microenvironment / Immunotherapy

Cite this article

Download citation ▾
Gang Liu. CD8+ T Cell Exhaustion and Tumor Immune Checkpoint Blockade: Mechanisms, Heterogeneity, and Combination Intervention Strategies. Advances in World Medical Research, 2026, 2 (3) : 96-104 DOI:10.71204/dkzdp879

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Abdel-Hakeem, M. S., Manne, S., Beltra, J. C., et al. (2021). Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation. Nature Immunology, 22(8), 1008-1019. https://doi.org/10.1038/s41590-021-00975-5

[2]

Ahmed, R., & Gray, D. (1996). Immunological memory and protective immunity: Understanding their relation. Science, 272(5258), 54-60. https://doi.org/10.1126/science.272.5258.54

[3]

Belk, J. A., Yao, W., Ly, N., et al. (2022). Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell, 40(7), 768-786.e7. https://doi.org/10.1016/j.ccell.2022.06.001

[4]

Cercek, A., Lumish, M., Sinopoli, J., et al. (2022). PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. New England Journal of Medicine, 386(25), 2363-2376. https://doi.org/10.1056/NEJMoa2201445

[5]

Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022). Clinical implications of T cell exhaustion for cancer immunotherapy. Nature Reviews Clinical Oncology, 19(12), 775-790. https://doi.org/10.1038/s41571-022-00689-z

[6]

Dolina, J. S., Van Braeckel-Budimir, N., Thomas, G. D., & Salek-Ardakani, S. (2021). CD8+ T cell exhaustion in cancer. Frontiers in Immunology, 12, Article 715234. https://doi.org/10.3389/fimmu.2021.715234

[7]

Forde, P. M., Spicer, J., Lu, S., et al. (2022). Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. New England Journal of Medicine, 386(21), 1973-1985. https://doi.org/10.1056/NEJMoa2202170

[8]

Giles, J. R., Ngiow, S. F., Manne, S., et al. (2022). Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics. Nature Immunology, 23(11), 1600-1613. https://doi.org/10.1038/s41590-022-01338-4

[9]

Gumber, D., & Wang, L. D. (2022). Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. eBioMedicine, 77, Article 103941. https://doi.org/10.1016/j.ebiom.2022.103941

[10]

Hashimoto, M., Kamphorst, A. O., Im, S. J., et al. (2018). CD 8 T cell exhaustion in chronic infection and cancer: Opportunities for interventions. Annual Review of Medicine, 69, 301-318. https://doi.org/10.1146/annurev-med-012017-043208

[11]

June, C. H., O’Connor, R. S., Kawalekar, O. U., et al. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361-1365. https://doi.org/10.1126/science.aar6711

[12]

Khan, O., Giles, J. R., McDonald, S., et al. (2019). TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature, 571(7764), 211-218. https://doi.org/10.1038/s41586-019-1325-x

[13]

Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022). The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nature Reviews Drug Discovery, 21(7), 509-528. https://doi.org/10.1038/s41573-021-00345-8

[14]

Kraehenbuehl, L., Weng, C. H., Eghbali, S., et al. (2022). Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nature Reviews Clinical Oncology, 19(1), 37-50. https://doi.org/10.1038/s41571-021-00552-7

[15]

Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., et al. (2022). Cancer vaccines: The next immunotherapy frontier. Nature Cancer, 3(8), 911-926. https://doi.org/10.1038/s43018-022-00418-6

[16]

Litchfield, K., Reading, J. L., Puttick, C., et al. (2021). Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell, 184(3), 596-614.e14. https://doi.org/10.1016/j.cell.2021.01.002

[17]

McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019). CD 8 T cell exhaustion during chronic viral infection and cancer. Annual Review of Immunology, 37, 457-495. https://doi.org/10.1146/annurev-immunol-041015-055318

[18]

Oliveira, G., & Wu, C. J. (2023). Dynamics and specificities of T cells in cancer immunotherapy. Nature Reviews Cancer, 23(5), 295-316. https://doi.org/10.1038/s41568-023-00560-y

[19]

Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12(4), 252-264. https://doi.org/10.1038/nrc3239

[20]

Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021). Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. British Journal of Cancer, 124(2), 359-367. https://doi.org/10.1038/s41416-020-01048-4

[21]

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., et al. (2021). Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L 1 tumor proportion score ≥ 50%. Journal of Clinical Oncology, 39(21), 2339-2349. https://doi.org/10.1200/JCO.21.00174

[22]

Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., et al. (2018). Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell, 175(4), 998-1013. https://doi.org/10.1016/j.cell.2018.10.038

[23]

Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348(6230), 56-61. https://doi.org/10.1126/science.aaa8172

[24]

Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022). Overcoming TGFβ-mediated immune evasion in cancer. Nature Reviews Cancer, 22(1), 25-44. https://doi.org/10.1038/s41568-021-00413-6

PDF (273KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉